Literature DB >> 12398940

Dexamethasone inhibits and thyroid hormone promotes differentiation of mouse chondrogenic ATDC5 cells.

T Siebler1, H Robson, S M Shalet, G R Williams.   

Abstract

The effects of glucocorticoid (GC) excess, thyrotoxicosis, and hypothyroidism on linear growth indicate that growth plate chondrocytes are exquisitely sensitive to GC and thyroid hormone (T(3)). Murine ATDC5 cells undergo chondrogenesis in vitro and were used to evaluate the effects of dexamethasone (Dex) and T(3) on cell proliferation and differentiation. Immature and differentiated ATDC5 cells expressed glucocorticoid and T(3)-receptor mRNAs. Cells proliferated and organized into cartilage-like nodules after 7 days. Chondrocyte maturation progressed over 9-40 days, with increasing alkaline phosphatase (ALP) activity, secretion of an Alcian blue-positive matrix, and mineralization of cartilage-like nodules. Dex reduced cell number over the 40 day period, causing inhibition of ALP activity and matrix production with failure of mineralization. Following withdrawal of Dex, chondrocytes proliferated and re-entered the differentiation and mineralization program, indicating that GC inhibition of chondrogenesis is reversible. In contrast, T(3) reduced cell proliferation, but induced ALP activity and increased matrix secretion earlier than in control cultures. Thus, GCs and T(3) regulate growth plate chondrocyte differentiation by distinct mechanisms. GCs arrest cell proliferation, differentiation, and cartilage mineralization and maintain chondrocyte precursors in a state of quiescence with the capacity to re-enter chondrogenesis. T(3) inhibits cell proliferation but accelerates differentiation to stimulate chondrogenesis. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12398940     DOI: 10.1016/s8756-3282(02)00855-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

Review 1.  Controlled differentiation of stem cells.

Authors:  Nathaniel S Hwang; Shyni Varghese; Jennifer Elisseeff
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

2.  Dexamethasone inhibits chondrocyte differentiation by suppression of Wnt/β-catenin signaling in the chondrogenic cell line ATDC5.

Authors:  Masako Naito; Akiko Ohashi; Tomihisa Takahashi
Journal:  Histochem Cell Biol       Date:  2015-06-24       Impact factor: 4.304

Review 3.  Juvenile thyrotoxicosis; can we do better?

Authors:  G Birrell; T Cheetham
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

4.  Clinical and endocrine features and long-term outcome of Graves' disease in early childhood.

Authors:  A T Bossowski; V Reddy; L A Perry; L B Johnston; K Banerjee; J C Blair; M O Savage
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

5.  Levels of bone collagen markers in preterm infants: relation to antenatal glucocorticoid treatment.

Authors:  Eftichia Korakaki; Dimitrios Gourgiotis; Agisilaos Aligizakis; Antonia Manoura; Eleftheria Hatzidaki; Emmanuel Giahnakis; Antonios Marmarinos; Maria Kalmanti; Christina Giannakopoulou
Journal:  J Bone Miner Metab       Date:  2007-04-20       Impact factor: 2.626

6.  Ablation of the pro-apoptotic protein Bax protects mice from glucocorticoid-induced bone growth impairment.

Authors:  Farasat Zaman; Dionisios Chrysis; Kirsten Huntjens; Bengt Fadeel; Lars Sävendahl
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

7.  Iodothyronine deiodinase enzyme activities in bone.

Authors:  Allan J Williams; Helen Robson; Monique H A Kester; Johannes P T M van Leeuwen; Stephen M Shalet; Theo J Visser; Graham R Williams
Journal:  Bone       Date:  2008-04-04       Impact factor: 4.398

8.  A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism.

Authors:  J H Duncan Bassett; Allan J Williams; Elaine Murphy; Alan Boyde; Peter G T Howell; Rowan Swinhoe; Marta Archanco; Frédéric Flamant; Jacques Samarut; Sabine Costagliola; Gilbert Vassart; Roy E Weiss; Samuel Refetoff; Graham R Williams
Journal:  Mol Endocrinol       Date:  2007-10-11

9.  Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development.

Authors:  Claudine G James; Veronica Ulici; Jan Tuckermann; T Michael Underhill; Frank Beier
Journal:  BMC Genomics       Date:  2007-07-01       Impact factor: 3.969

10.  GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty.

Authors:  Shunye Zhu; Lingli Long; Yue Hu; Ying Tuo; Yubin Li; Zhenhua Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-09       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.